| P/E (FY) | — | Sales (TTM) | $587.9M |
| Earnings (TTM) | -$72.9M | ROE | −17.14% |
| Net Margin | −37.19% | ROIC | −7.06% |
| Debt / Equity | 0.27 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −15.45% |
OPKO Health is a healthcare company operating in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally through Pharmaceutical and Diagnostics segments. The Pharmaceutical segment develops antibody candidates such as MDX2001, MDX2003, and MDX2004 targeting solid and hematological tumors, an Epstein Barr Virus vaccine, the extended-release product Rayaldee, and the recombinant human growth hormone NGENLA, among other products.
| Market Cap | $1.02B | Trading Days | 5294 |
| 52W High | 1.73 |
| 52W Low | 0.98 |
| % Off High | −21.10% |
| YTD | 8.33% | 1Y | 1.11% |
| 3Y | −26.61% | 5Y | −63.40% |
| 10Y | −86.28% | Since incept. (ann.) | 6.26% |
US 72% · CL 10% · IE 8% · ES 4% · …
| Ann. Volatility (1Y) | 54.00% | Ann. Volatility (3Y) | 53.83% |
| Sharpe (1Y) | 0.28 | Sharpe (3Y) | 0.09 |
| Max Drawdown (1Y) | −30.38% | Max Drawdown (3Y) | −56.51% |
| Beta (3Y, vs SPY) | 1.15 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.03B | — |
| LBRX | LB PHARMACEUTICALS INC | $1.00B | — |
| AVTX | Avalo Therapeutics, Inc. | $999.3M | — |
| PCRX | Pacira BioSciences, Inc. | $1.04B | 165.0 |
| BIOA | BioAge Labs, Inc. | $986.4M | — |
| SPTX | Seaport Therapeutics, Inc. | $1.06B | — |
| OLMA | Olema Pharmaceuticals, Inc. | $977.4M | — |
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
| SVRA | Savara Inc | $1.08B | — |
| JBIO | Jade Biosciences, Inc. | $955.1M | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $952.3M |
| — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $951.3M | — |